{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:17:48Z","timestamp":1780319868541,"version":"3.54.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"38","funder":[{"name":"Ilyang pharmacology","award":["no"],"award-info":[{"award-number":["no"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1097\/md.0000000000022137","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T18:03:08Z","timestamp":1600452188000},"page":"e22137","source":"Crossref","is-referenced-by-count":7,"title":["The prolongation effect of ilaprazole-based standard triple therapy for Helicobacter pylori"],"prefix":"10.1097","volume":"99","author":[{"given":"Seung Woo","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Jin","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sae Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Hee","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Ho","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Moon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Kyu","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Soo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,9,18]]},"reference":[{"key":"R1-20230103","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","article-title":"Management of Helicobacter pylori infection-the Maastricht V\/Florence consensus report","volume":"66","author":"Malfertheiner","year":"2017","journal-title":"Gut"},{"key":"R2-20230103","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/ajg.2016.563","article-title":"ACG Clinical Guideline: treatment of Helicobacter pylori infection","volume":"112","author":"Chey","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"R3-20230103","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1517\/17425255.2013.813018","article-title":"The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment","volume":"9","author":"de Bortoli","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R4-20230103","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1523-5378.2006.00459.x","article-title":"2-week triple therapy for Helicobacter pylori infection is better than 1-week in clinical practice: a large prospective single-center randomized study","volume":"11","author":"Paoluzi","year":"2006","journal-title":"Helicobacter"},{"key":"R5-20230103","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1067\/mcp.2000.109155","article-title":"A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease","volume":"68","author":"Periclou","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"R6-20230103","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/MCG.0b013e3181e88515","article-title":"A new PPI, ilaprazole compared with omeprazole in the treatment of duodenal ulcer: a randomized double-blind multicenter trial","volume":"45","author":"Wang","year":"2011","journal-title":"J Clin Gastroenterol"},{"key":"R7-20230103","doi-asserted-by":"crossref","first-page":"7","DOI":"10.9790\/0853-13170712","article-title":"Comparative study of Omeprazole, Rabeprazole and Ilaprazole for their efficacy in patient suffering from reflux esophagitis with symptoms","volume":"13","author":"Kumar","year":"2014","journal-title":"IOSR-JDMS"},{"key":"R8-20230103","doi-asserted-by":"crossref","first-page":"208","DOI":"10.5056\/jnm16087","article-title":"Esophageal acidification during nocturnal acid-breakthrough with ilaprazole versus omeprazole in gastroesophageal reflux disease","volume":"23","author":"Karyampudi","year":"2017","journal-title":"J Neurogastroenterol Motil"},{"key":"R9-20230103","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1185\/03007995.2011.639353","article-title":"Ilaprazole for the treatment of duodenal ulcer: a randomized, double-blind and controlled phase III trial","volume":"28","author":"Wang","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"R10-20230103","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00535-009-0072-4","article-title":"Randomized, parallel, double-blind comparison of the ulcer-healing effects of ilaprazole and omeprazole in the treatment of gastric and duodenal ulcers","volume":"44","author":"Ho","year":"2009","journal-title":"J Gastroenterol"},{"key":"R11-20230103","doi-asserted-by":"crossref","first-page":"6310","DOI":"10.3748\/wjg.v21.i20.6310","article-title":"Modified sequential therapy vs quadruple therapy as initial therapy in patients with Helicobacter infection","volume":"21","author":"Liao","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R12-20230103","doi-asserted-by":"crossref","first-page":"1654907","DOI":"10.1155\/2017\/1654907","article-title":"Efficacy and safety of the triple therapy containing Ilaprazole, Levofloxacin, and Amoxicillin as first-Line treatment in Helicobacter pylori infections","volume":"2017","author":"Ahn","year":"2017","journal-title":"Gastroenterol Res Pract"},{"key":"R13-20230103","doi-asserted-by":"crossref","first-page":"1648047","DOI":"10.1155\/2016\/1648047","article-title":"High dose Ilaprazole\/Amoxicillin as first-line regimen for Helicobacter pylori infection in Korea","volume":"2016","author":"Kwack","year":"2016","journal-title":"Gastroenterol Res Pract"},{"key":"R14-20230103","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12441","article-title":"Helicobacter pylori eradication rates of concomitant and sequential therapies in Korea","volume":"22","author":"Kim","year":"2017","journal-title":"Helicobacter"},{"key":"R15-20230103","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3346\/jkms.2014.29.5.704","article-title":"Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: is it time to change?","volume":"29","author":"Gong","year":"2014","journal-title":"J Korean Med Sci"},{"key":"R16-20230103","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.3748\/wjg.v20.i6.1517","article-title":"Second and third line treatment options for Helicobacter pylori eradication","volume":"20","author":"Song","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R17-20230103","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12392","article-title":"Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies","volume":"22","author":"Gisbert","year":"2017","journal-title":"Helicobacter"},{"key":"R18-20230103","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1523-5378.2007.00468.x","article-title":"Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea","volume":"12","author":"Kim","year":"2007","journal-title":"Helicobacter"},{"key":"R19-20230103","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1523-5378.2008.00648.x","article-title":"Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea","volume":"13","author":"Kim","year":"2008","journal-title":"Helicobacter"},{"issue":"(suppl)","key":"R20-20230103","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1136\/gut.43.2008.S56","article-title":"The life and death of Helicobacter pylori","volume":"43","author":"Scott","year":"1998","journal-title":"Gut"},{"key":"R21-20230103","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s11938-018-0206-y","article-title":"Potent acid suppression with PPIs and P-CABs: what's new?","volume":"16","author":"Hunt","year":"2018","journal-title":"Curr Treat Options Gastroenterol"},{"key":"R22-20230103","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/MEG.0b013e3283496502","article-title":"A randomized trial of standard-dose versus half-dose rabeprazole, clarithromycin, and amoxicillin in the treatment of Helicobacter pylori infection","volume":"23","author":"Mansour","year":"2011","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R23-20230103","doi-asserted-by":"crossref","first-page":"201","DOI":"10.5009\/gnl.2010.4.2.201","article-title":"The influence of CYP2C19 polymorphism on eradication of Helicobacter pylori: a prospective randomized study of lansoprazole and rabeprazole","volume":"4","author":"Lee","year":"2010","journal-title":"Gut Liver"},{"key":"R24-20230103","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s10620-014-3093-7","article-title":"Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance","volume":"59","author":"Lee","year":"2014","journal-title":"Dig Dis Sci"},{"key":"R25-20230103","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1365-2036.2012.05211.x","article-title":"Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection","volume":"36","author":"McNicholl","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"R26-20230103","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1523-5378.2008.00643.x","article-title":"Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis","volume":"13","author":"Zhao","year":"2008","journal-title":"Helicobacter"},{"key":"R27-20230103","doi-asserted-by":"crossref","first-page":"e12574","DOI":"10.1111\/hel.12574","article-title":"Personalized therapy for Helicobacter pylori: CYP2C19 genotype effect on first-line triple therapy","volume":"24","author":"Ar\u00e9valo Galvis","year":"2019","journal-title":"Helicobacter"},{"key":"R28-20230103","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/17425255.2018.1461835","article-title":"Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine","volume":"14","author":"El Rouby","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R29-20230103","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/00042737-200111000-00007","article-title":"Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia","volume":"13","author":"Gisbert","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R30-20230103","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/hel.12221","article-title":"Is there any difference in the eradication rate of helicobacter pylori infection according to the endoscopic stage of peptic ulcer disease?","volume":"20","author":"Seo","year":"2015","journal-title":"Helicobacter"},{"key":"R31-20230103","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1365-2036.2004.02283.x","article-title":"Standard treatment for Helicobacter pylori infection is suboptimal in non-ulcer dyspepsia compared with duodenal ulcer in Chinese","volume":"21","author":"Wong","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"R32-20230103","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4166\/kjg.2009.54.5.269","article-title":"Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea","volume":"54","author":"Kim","year":"2009","journal-title":"Korean J Gastroenterol"}],"updated-by":[{"DOI":"10.1097\/md.0000000000024431","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000}}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022137","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T21:33:28Z","timestamp":1672781608000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,18]]},"references-count":32,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000022137","relation":{"correction":[{"id-type":"doi","id":"10.1097\/MD.0000000000024431","asserted-by":"object"}]},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,18]]}}}